Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.

Telli, Melinda L.; Metzger, Otto; Timms, Kirsten M.; Evans, Brent; Vogel, Diana; Wei, Helen; Jones, Joshua T.; Wenstrup, Richard J.; McKee, Mark D.; Sullivan, Danielle; Fallstrom, Mathias; Maag, David; Ansell, Peter; Sohn, Joohyuk; Chen, Shou‐Tung; Martínez, Noelia; Geyer, Charles E.; Loibl, Sibylle; Golshan, Mehra

doi:10.1200/jco.2018.36.15_suppl.519

Cited by 34 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During the initial analysis it was found that the addition of carboplatin to paclitaxel increased the pCR rate, whereas the addition of veliparib brought no further increase in the pCR 27 . Another analysis recently examined the relationship between HRD and the effectiveness of the treatments in this study 28 . Higher pCR rates were noted in patients with HRD across all three treatment arms.…”

Section: Advanced Breast Cancer – the Triple-negative Patientmentioning

confidence: 97%

“…However, the patients receiving carboplatin were found to have higher pCR rates in both the HRD-positive and the HRD-negative subgroups. The treatment with doxorubicin and cyclophosphamide in all patients could explain the missing correlation between the HRD status and the randomisation arms 28 . It could also be the case that the specific tests for identifying HRD do not suffice for PARP inhibitor therapy.…”

Section: Advanced Breast Cancer – the Triple-negative Patientmentioning

confidence: 99%

“…Während die initiale Auswertung zeigte, dass die Hinzunahme von Carboplatin zu Paclitaxel die pCR-Rate erhöhte, brachte die Hinzunahme von Veliparib keine weitere Steigerung der pCR 27 . In einer weiteren Analyse wurde kürzlich der Zusammenhang zwischen HRD und der Wirksamkeit der Therapien in dieser Studie untersucht 28 . Es wurden höhere pCR-Raten bei Patientinnen mit HRD in allen 3 Therapiearmen beobachtet.…”

Section: Das Fortgeschrittene Mammakarzinom – Die Triple-negative Patunclassified

“…Allerdings hatten Patientinnen, die Carboplatin erhalten haben, höhere pCR-Raten sowohl in den HRD-positiven als auch in den HRD-negativen Subgruppen. Die Therapie mit Doxorubicin und Cyclophosphamid bei allen Patientinnen könnte eine Erklärung für die fehlende Korrelation zwischen HRD-Status und den Randomisationsarmen sein 28 . Es könnte aber auch sein, dass die spezifischen Tests, die eine HRD anzeigen, für eine Therapie mit PARP-Inhibitoren nicht ausreichen.…”

Section: Das Fortgeschrittene Mammakarzinom – Die Triple-negative Patunclassified

See 3 more Smart Citations

Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer

Müller

Wöckel

Lux

et al. 2018

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

New therapeutic developments aimed at treating women with advanced breast cancer currently focus both on identifying patients eligible for targeted therapeutic concepts and on the continuing development of immune therapies. The data on CDK4/6 inhibitors are now complete and consistent in this class of substances (palbociclib, ribociclib and abemaciclib). Further pathways under investigation are PI3K and AKT signalling pathways along with diverse approaches to their inhibition. Initial study results were also presented recently on both mechanisms of action. Insights into the PARP inhibitors, moreover, are increasing; studies in this respect are also examining in which population they can be used most effectively. This review offers a summary of the recent studies and an outline of the latest developments.

show abstract

Section: Advanced Breast Cancer – the Triple-negative Patientmentioning

confidence: 97%

Section: Advanced Breast Cancer – the Triple-negative Patientmentioning

confidence: 99%

Section: Das Fortgeschrittene Mammakarzinom – Die Triple-negative Patunclassified

See 2 more Smart Citations

Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer

Müller

Wöckel

Lux

et al. 2018

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

show abstract

“…Noteworthy, the lack of cyclophosphamide in the control arm might have amplified the observed carboplatin effect [21]. In a recent analysis of the BrighTNess trial, higher rates of pCR were observed in both HRD-positive and HRD-negative patients receiving carboplatin, although higher pCR rates were obtained in HRDpositive patients regardless of treatment arm [22].…”

Section: Over the Hedge Of Brca1/2 Mutationsmentioning

confidence: 99%